SCHEMBL5334104

SCHEMBL5334104

Nc1ccc(Oc2cc(-c3ncco3)ncn2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LTA4H P09960 2/20 0.42
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
APAF1 O14727 1/20 0.38
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MITF O75030 1/20 0.33
MAPT P10636 1/20 0.33
GFER P55789 1/20 0.33
NLRP1 Q9C000 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379857 0.85 NPC1 (0.43) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL5444260 0.80 RAB9A (0.42) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL5460155 0.79 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL14031552 0.74 CYP2C19 (0.37) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL3041342 0.74 LTA4H (0.73) SMN1; SMN2RAB9ANPC1LTA4HMEN1
SCHEMBL14447596 0.72 KMO (0.44) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL1892882 0.72 ALDH1A1 (0.48) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL5450758 0.70 NPC1 (0.44) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9
SCHEMBL20931741 0.70 MEN1 (0.52) SMN1; SMN2RAB9ANPC1MEN1KMT2A
SCHEMBL5429409 0.69 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 SMN1; SMN2 3885/4885RAB9A 1640/4885NPC1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.